Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

es 13,012 17,622 Accrued expenses 7,132 9,923 Deferred revenue, current portion 9,547 10,010 Other current liabilities 3,558 5,417 ----- ----- Total current liabilities $49,357 $68,374 Convertible subordinated notes 214,955 214,955 Capital lease obligations 19,228 20,347 Deferred revenue 53,308 55,567 Deferred gain 5,245 5,901 Other long-term liabilities 4,458 5,238 ----- ----- Total liabilities $346,551 $370,382 Commitments and contingencies Stockholders' equity: Preferred stock $- $- Common stock 9 9 Capital in excess of par value 1,323,907 1,312,796 Accumulated other comprehensive income 1,117 1,439 Accumulated deficit (1,218,933) (1,124,090) ---------- ---------- Total stockholders' equity $106,100 $190,154 -------- -------- Total liabilities and stockholders' equity $452,651 $560,536 ======== ======== (1) The consolidated balance sheet at December 31, 2008 has been derived from the audited financial sta
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Jolla, CA (PRWEB) August 19, 2014 ... toll Parkinson’s disease can take on an individual. ... extremities, decreased facial expression, problems swallowing and severe depression. ... to the dying off of dopamine producing neurons of ... themselves from a disease that slowly and progressively gets ...
(Date:8/19/2014)... 19, 2014 CSSi, the leader in patient ... the formation of the company,s Medical and Clinical Advisory ... of Dr. William E. Gannon, Jr. to ... The MCAB, with Dr. Gannon,s leadership, ... areas and set strategic goals for the advancement and ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... The following was,released today by the Tech Council of ... that is paying off but,it must be safeguarded and ... other states seek 21st century,economic engines we Marylanders can ... drivers, the bioscience industry. This blossoming industry,has expanded over ...
... a New Generation of Drug Candidates ... for Inflammatory ... Germany,September 10 Cellzome Inc. and GlaxoSmithKline (LSE & NYSE:,GSK) ... and market novel kinase-targeted therapeutics to treat inflammatory,diseases., The ...
... that a research scientist and university professor gets to see his ... months, Richard W. Siegel will get to watch his name scroll ... new title that seems light years away from laboratory benches and ... has been a three-year labor of love for Siegel. From securing ...
Cached Biology Technology:Protect Maryland's Bioscience Industry 2Protect Maryland's Bioscience Industry 3GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 2GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 3GlaxoSmithKline and Cellzome Announce Major Strategic Alliance 4Professor-turned-producer learns the movie biz 2Professor-turned-producer learns the movie biz 3Professor-turned-producer learns the movie biz 4Professor-turned-producer learns the movie biz 5
(Date:8/20/2014)... Women who are poor experience higher cortisol levels ... levels of the stress hormone, putting them at ... to a new research from the University of Colorado ... American Journal of Human Biology , is the ... directly to the socioeconomic status of their mothers during ...
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Worker bees 'know' when to invest in their reproductive future 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... island of Madagascar harbors a unique biodiversity that evolved ... Numerous plant and animal species are found solely on ... most prominent representatives of the island,s unique fauna. They ... are two species of the genus Eulemur that also ...
... African Australians Inc Award at Parliament House on ... remarkable contributions to Australia, Africa and the world ... engagement by African Australians." Professor Hayes heads ... Institute of Medical Research, while also holding a ...
... New research findings from the Centre for Permafrost (CENPERM) ... University of Copenhagen, document that permafrost during thawing may ... the atmosphere and that the future water content in ... permafrost thawing. The findings may lead to more accurate ...
Cached Biology News:Scientists from Mainz and Antananarivo describe Lavasoa Dwarf Lemur as new primate species 2Professor Vanessa Hayes awarded for exceptional Africa-related work 2Professor Vanessa Hayes awarded for exceptional Africa-related work 3New knowledge about permafrost improving climate models 2
... by R. Edwards (1996) • ... types of immunoassays, including RIA, ... and on the photoluminescent and ... information is also given on ...
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Request Info...
Biology Products: